Not Losing Weight on Tirzepatide?
GLP-1 agonists are highly effective for the vast majority of users, but plateaus and non-response do happen. Here are the most common causes and how to fix them.
This guide applies to Tirzepatide, Retatrutide, Semaglutide, and all GLP-1 class peptides.
Education only: This page describes what clinical trials and product labeling report. It is not medical advice and not a dosing protocol. Dose selection and any change to a regimen are decisions for a licensed prescriber. Nothing here tells you to start, stop, or adjust a dose.
Common Causes & Fixes
Dose too low
Starting doses are designed for tolerance, not weight loss. In the registrational trials, most of the weight loss showed up at the higher maintenance doses, not at the starting dose. A flat response after several weeks at a starting dose is one of the things a prescriber weighs when reviewing a regimen.
Dose changes are a clinical decision. A prescriber decides whether and when to adjust, based on tolerance and response. This is not something to self-direct.
Underdosed product
Research-grade peptides can contain less than labeled. A vial claiming 10mg may only contain 7 to 8mg due to manufacturing variances or intentional underdosing.
Verify COA from a third-party lab. Source from a reputable, COA-verified supplier.
Caloric compensation ("eating around the drug")
GLP-1s reduce appetite but do not eliminate it. Some people unconsciously compensate for reduced meal size with more frequent snacking or higher-calorie choices.
Track food intake for one week using an app. Most people are surprised by the results.
Insufficient deficit
GLP-1s create a deficit primarily by reducing appetite. If maintenance calories are very high, the deficit created may be smaller than expected.
Assess total daily energy expenditure and ensure a meaningful deficit (500 to 750 kcal/day) is being maintained.
Water retention masking fat loss
The body retains water during periods of metabolic change, especially early in a protocol. Weight on the scale may be flat while fat is still being lost.
Use body measurements (waist, hip) alongside scale weight. Take weekly photos. Trust the process for at least 8 weeks.
Metabolic adaptation
After significant weight loss, basal metabolic rate decreases. The same deficit that worked at a higher weight may not be enough later.
Consider a diet break (eating at maintenance for 2 weeks), then resume. Reassess caloric targets based on new body weight.
Degraded or improperly stored peptide
Tirzepatide stored at room temperature degrades rapidly. If your product was warm during shipping or storage, potency may be significantly reduced.
Cold-chain shipping and refrigerated storage preserve potency. Product that warmed during transit, or was frozen after reconstitution, can lose potency and blunt results.
When to Seek Help
If you have ruled out all of the above and are still not losing weight after a sustained period at a maintenance dose, consider consulting a physician who can assess for underlying metabolic conditions (thyroid, insulin resistance, PCOS) that may be blunting response.